News
MCRB
8.81
-4.96%
-0.46
Weekly Report: what happened at MCRB last week (0330-0403)?
Weekly Report · 1d ago
Weekly Report: what happened at MCRB last week (0323-0327)?
Weekly Report · 03/30 10:18
Weekly Report: what happened at MCRB last week (0316-0320)?
Weekly Report · 03/23 10:15
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date
TipRanks · 03/16 21:03
Weekly Report: what happened at MCRB last week (0309-0313)?
Weekly Report · 03/16 10:14
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/13 18:33
Seres Therapeutics Price Target Maintained With a $22.00/Share by Canaccord Genuity
Dow Jones · 03/13 18:33
Canaccord Genuity Remains a Buy on Seres Therapeutics (MCRB)
TipRanks · 03/13 11:59
Seres Therapeutics GAAP EPS of $0.64, revenue of $0.78M
Seeking Alpha · 03/12 19:38
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline
TipRanks · 03/12 12:08
Seres Therapeutics reports FY25 EPS 64c
TipRanks · 03/12 11:15
*Seres Therapeutics 2025 EPS 64c >MCRB
Dow Jones · 03/12 11:15
*Seres Therapeutics 2025 Rev $789,000 >MCRB
Dow Jones · 03/12 11:15
Seres Therapeutics posts 2025 profit as expenses fall
Reuters · 03/12 11:14
Earnings Scheduled For March 12, 2026
Benzinga · 03/12 11:11
Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate
Benzinga · 03/12 11:10
Seres Therapeutics FY2025 net income from continuing operations was USD 5.7 million
Reuters · 03/12 11:08
BRIEF-Seres Therapeutics FY EPS USD 0.64
Reuters · 03/12 11:00
Seres Therapeutics: Q4 Earnings Snapshot
Barchart · 03/12 06:23
Seres Therapeutics Files Initial Beneficial Ownership Statement for EVP and COO Brady Kelly M. Brady
Reuters · 03/11 22:31
More
Webull provides a variety of real-time MCRB stock news. You can receive the latest news about Seres Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MCRB
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.